Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
35.48
+0.83 (2.40%)
Mar 6, 2026, 4:00 PM EST - Market closed
Stoke Therapeutics Employees
Stoke Therapeutics had 128 employees as of December 31, 2024. The number of employees increased by 18 or 16.36% compared to the previous year.
Employees
128
Change (1Y)
18
Growth (1Y)
16.36%
Revenue / Employee
$1,606,500
Profits / Employee
$316,930
Market Cap
2.03B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 800 |
| Ascentage Pharma Group International | 605 |
| Syndax Pharmaceuticals | 298 |
| Celldex Therapeutics | 198 |
| Soleno Therapeutics | 182 |
| Tango Therapeutics | 155 |
| Aurinia Pharmaceuticals | 128 |
| Mesoblast | 81 |
STOK News
- 3 days ago - The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome - Business Wire
- 11 days ago - Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - Business Wire
- 17 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 24 days ago - Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) - Business Wire
- 4 weeks ago - Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Business Wire
- 5 weeks ago - Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA - PRNewsWire
- 7 weeks ago - Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity - Seeking Alpha
- 7 weeks ago - Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome - Business Wire